Clinical Trial Update: Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) [Phase 2]

View source ↗

Summary

Phase 2 study assessing the effect of gefapixant (MK-7264/AF-219) on cough reflex sensitivity in healthy participants and individuals with refractory chronic co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2018-02-15